Review Article

Clinical narrative: autoimmune hepatitis

  • The American Journal of Gastroenterology (2018)
  • doi:10.1038/s41395-018-0058-z
  • Download Citation
Received:
Accepted:
Published:

Subjects

Abstract

Autoimmune hepatitis (AIH) is an inflammatory liver disease that is characterized by circulating autoantibodies, hypergammaglobulinemia, and a lymphoplasmocytic infiltration with interface hepatitis on liver biopsy. Treatment with corticosteroids and other immunosuppressive agents is effective and early diagnosis can result in near-normal life expectancy. Untreated patients, however, can progress to cirrhosis and liver failure. The clinical presentation is heterogeneous and may pose diagnostic and therapeutic dilemmas. This case-based review will address the diagnosis and management of this disease, in addition to difficult but commonly encountered clinical scenarios.

  • Subscribe to The American Journal of Gastroenterology for full access:

    $870

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998–1005.

  2. 2.

    Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.

  3. 3.

    Muratori P, Granito A, Quarneti C, et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol. 2009;50:1210–18.

  4. 4.

    Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102:1005–12.

  5. 5.

    Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41:677–83.

  6. 6.

    Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394–401.

  7. 7.

    Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213.

  8. 8.

    Lohse AW, Chazouilleres O, Dalekos G, et al. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004.

  9. 9.

    Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824–32.

  10. 10.

    Pratt DS, Fawaz KA, Rabson A, et al. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology . 1997;113:664–68.

  11. 11.

    Stravitz RT, Lefkowitch JH, Fontana RJ, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53:517–26.

  12. 12.

    Hennes EK, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.

  13. 13.

    Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540–48.

  14. 14.

    Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.

  15. 15.

    Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010;53:191–98.

  16. 16.

    Heneghan MA, Allan ML, Bornstein JD, et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol. 2006;45:584–91.

  17. 17.

    Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–206.

  18. 18.

    Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–33.

  19. 19.

    Nguyen TM, Daubard M, Le Gall C, et al. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis. Ther Drug Monit. 2010;32:433–37.

  20. 20.

    Dhaliwal HK, Anderson R, Thornhill EL, et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology. 2012;56:1401–8.

  21. 21.

    Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology. 1981;80:687–92.

  22. 22.

    Zachou K, Gatselis N, Papadamou G, et al. Mycophenolate for the treatment of autoimmune hepatitis prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol. 2011;55:636–46.

  23. 23.

    Czaja AJ. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol. 2012;26:615–20.

  24. 24.

    Aw MM, Dhawan A, Samyn M, et al. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow up. J Hepatol. 2009;51:156–60.

  25. 25.

    Mistilis SP, Vickers CR, Darroch MH, et al. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust. 1985;143:463–5.

  26. 26.

    Nasseri-Moghaddam S, Nikfam S, Karimian S, et al. Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis; interim analysis report of a randomized controlled trial. Middle East J Dig Dis. 2013;5:193–200.

  27. 27.

    Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771–6.

  28. 28.

    Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant. 2005;5:1085–9.

  29. 29.

    Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med. 2014;127:1128–31.

  30. 30.

    Santos ES, Arosemena LR, Raez LE, et al. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int. 2006;26:625–9.

  31. 31.

    Evans JT, Shepart MM, Oates JC, et al. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008;42:862–3.

  32. 32.

    Carey EJ, Somaratne K, Rakela J. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Rev Med Chil. 2011;139:1484–7.

  33. 33.

    Burak KW, Swain MG, Santodomingo-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27:273–80.

  34. 34.

    Buchel E, Steenbergen WV, Nevens F, et al. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol. 2002;97:3160–5.

  35. 35.

    Westbrook RH, Yeoman AD, Kriese S, et al. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun. 2012;38:J239–44.

  36. 36.

    Christopher V, Al-Chalabi T, Richardson PD, et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transplant. 2006;12:1138–43.

  37. 37.

    Werner M, Bjornsson E, Prytz H, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol. 2007;42:986–91.

  38. 38.

    Heneghan MA, Norris SM, O’Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut. 2001;48:97–102.

  39. 39.

    Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011;140:1980–9.

  40. 40.

    Gleeson D, Heneghan MA, et al. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611–29.

  41. 41.

    Schramm C, Bubenheim M, O’Grady JG, et al. Long-term outcome of patients transplanted for autoimmune hepatitis: analysis of the European Liver Transplant Registry. J Hepatol. 2008;48:S47.

  42. 42.

    Neuberger J, Portmann B, Calne R, et al. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation. 1984;37:363–5.

  43. 43.

    Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transplant. 2006;12:1813–24.

  44. 44.

    Gassert DJ, Garcia H, Tanaka K, et al. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52:2433–37.

  45. 45.

    Ichai P, Duclos-Vallee JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13:996–1003.

  46. 46.

    Czaja AJ. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci. 2013;58:897–914.

  47. 47.

    Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931–39.

  48. 48.

    Foureau DM, Walling TL, Maddukuri V, et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol. 2015;180:40–51.

Download references

Author information

Affiliations

  1. Division of Hepatology, Carolinas Healthcare, Charlotte, NC, USA

    • Paul A Schmeltzer MD
    •  & Mark W Russo MD, MPH

Authors

  1. Search for Paul A Schmeltzer MD in:

  2. Search for Mark W Russo MD, MPH in:

Guarantor of the article

Mark Russo, MD, MPH.

Specific author contributions

MR: concept, writing manuscript, PS: Writing manuscript revisions.

Financial support

None.

Potential competing interests

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Mark W Russo MD, MPH.